Agonistic AT 1 receptor autoantibodies (AT 1 -AAs) have been described in the patients with malignant hypertension or preeclampia. Furthermore, AT 1 -AAs were highly associated with refractory hypertension. Function of vascular smooth muscle cells (VSMCs) is important in the regulation of blood pressure. We investigated and compared the ability of angiotensin II (Ang II) and AT 1 -AAs to stimulate the intracellular calcium mobilization and cellular proliferation of rat VSMCs. Twenty-two patients with refractory hypertension, 24 patients with non-refractory hypertension and 37 normotensives were recruited. The serum of each patient was detected for the presence of 
Introduction
Only 2.9% hypertensive patients in China have blood pressure (BP) levels that are well controlled (1) . Hypertension in some of these patients persists despite multiple antihypertensive medications and excellent compliance. Refractory hypertension is conventionally defined as systolic or diastolic BP that remains uncontrolled despite sustained therapy with at least three different classes of antihypertensive agents. True refractory hypertension is estimated to affect less than 5% of the general population with hypertension (2) . However, these patients are at greater risk for stroke, renal insufficiency and morbid cardiovascular events than BP well-controlled patients (3) . Many factors including obesity, excessive dietary salt ingestion, alcohol consumption and sleep apnea are found contributing to resistance to antihypertensive therapy (4, 5) .
Agonistic AT 1 receptor autoantibodies (AT 1 -AAs) were first described by Wallukat et al. (6) . The patients with preeclampsia developed the autoantibodies capable of activating the angiotensin II receptor type 1 (AT 1 receptor). AT 1 -AAs were also found in other severe hypertensive conditions including malignant hypertension and secondary hypertension (7) . However, their potential contribution to refractory hypertension has received little attention. In our previous studies, we found that AT 1 -AAs were highly associated with refractory hypertension (8) . And they were also found to be associated with stroke in hypertensive patients (9) .
In the previous studies, AT 1 -AAs were suggested to play an important role in the pathogenesis of preeclampsia. AT 1 -AAs induced signaling in vascular cells and trophoblasts including activator protein-1 (AP-1) and nuclear factorkappa B (NF-κB) (10, 11) , and activated calcineurin-NFAT (nuclear factor of activated T cells) through increased intracellular Ca 2+ mobilization in Chinese hamster ovary cells transferred with the rat AT 1A receptor (12) . However, there were limited data related to the role of AT 1 
Materials and Methods

Patients
This study was approved by the Ethics Committee of Union Hospital. The patients with essential hypertension participated in the study after written permission. Exclusion criteria included renal disease, liver disease, chronic inflammatory disease, sleep apnea, malignant hypertension and secondary hypertension. And patients with autoantibodies against α 1 -adrenergic receptor in circulation were also excluded. Prior to drug therapy, all the patients were advised to reduce dietary sodium intake and alcohol consumption. Hypertension was treated systemically in an open trial with a stepwise dosing regimen. All patients were treated with the long-acting calcium antagonist felodipine of 5 mg once a day for 2 weeks. Additional drugs and dose increments were prescribed in two further steps. Hydrochlorothiazide 12.5 mg/d and metoprolol 50 mg/d or enalapril 10 mg/d were added if BP was greater than 140/90 mmHg after two weeks of felodipine administration. Then, after two additional weeks, if BP was not below 140/90 mmHg, the doses of felodipine and metoprolol or enalapril were doubled for an additional 4 weeks. Hypertension was considered refractory if BP cannot be reduced to target level after combination three drugs therapy. According to the decrease of BP, the patients were assigned to two groups, a refractory hypertension (RH) group and a non-refractory (NRH) group. Twenty-two patients with refractory hypertension were recruited randomly. Twenty-four gender-, ageand weight-matched patients were selected as the NRH group. And the control group included 37 normotensives. The clinical data of the subjects are presented in Table 1 . Blood samples for the tests were obtained from each participant.
Peptide synthesis
Two different peptides were synthesized by the type PSSM-8 Peptide Synthesizer (Shimadzu Company, Japan). The peptides had the following amino acid sequences: P1, IHRNVFFIENTNITVCAFHYESQNSTL; and P2, AFHYESQ. P1 corresponding to the second extracelluar loop of the human AT 1 receptor was used in the ELISA assay and preparation of the immunoglobulin (Ig) fractions. P2 corresponding to portion of the second extracelluar loop of the human AT 1 receptor was an epitope recognized by AT 1 -AAs from preeclamptic individuals (6) , and was used in antibody neutralization experiment.
Preparation of Ig fraction
The serum of each patient was checked for the presence of AT 1 -AAs by ELISA, which was performed as described previously (8) , the titer was shown by the value of P/N when the sera were diluted in 1:40 [(P/N = (the A value of test − the A value of blank) / (the A value of negative control − the A value of blank)]. Preparation of the Ig fractions was outlined in detail earlier (6) . Briefly, the Ig fractions in the sera were isolated by ammonium sulfate precipitation at a saturation of 40%. The Ig fractions from positive AT 1 -AAs sera were loaded on a sepharose 4B CNBr-activated gel (Pharmacia, USA) to which the P2 peptide was covalently linked. The antibodies were eluted with 3 mol/L potassium thiocyanate (pH = 7.4) followed by immediate extensive dialysis against phosphate buffered saline; the purity was detected by SDS-PAGE.
Cell culture
Rat AT 1A receptors, an important subset of AT 1 receptors which are abundantly expressed in VSMCs, show a high degree of sequence identity to the human AT 1 receptor (16, 17) . We used VSMCs from Sprague Dawley rats (200-250 g) in this study. VSMCs were isolated after a well established procedure (18) . Briefly, the vessels of the rat thoracic aortae were cleared of fat and incubated for 10 min at 37°C in Hanks' balanced salt solution containing 0.2 mg/ml elastase type III (Sigma, USA), 2 mg/ml collagenase type II (Gibco, USA) and 0.1 mg/ml soybean trypsin inhibitor (Sigma, USA). This procedure ensured removal of the endothelial cells. The cleaned vessels were cut into 1-to 2-mm pieces and digested in the fresh Hanks' balanced salt solution with enzyme. The cell suspension was centrifuged at 200 × g for 5 minutes, and the pellet was resuspended in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) containing 10% heatinactivated fetal calf serum (Gibco, USA), 2 mmol/L Lglutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For measurement of [Ca 2+ ]i, the dispersed cells were aliquoted into 35 mm glass dishes (BD, USA) at 37°C in a humidified 5% CO 2 . And cells were studied between day 5 and day 7 of the primary culture. Cells in subculture passages 5-10 were used for the measurement of cellular proliferation.
Cell culture purity was routinely tested with smooth muscle α-actin staining.
Immunofluorescence Immunofluorescence was done as described previously (6). AT 1 -AAs at 1:40 dilution were used as first antibodies. FITC conjugated anti-human IgG (Zhongshan Biological Technology Ltd, China) was used as secondary antibody. And the Ig fractions from AT 1 -AAs negative sera were used as the negative control (control IgG). The preparations were observed in a fluorescent microscope (Nikon, Japan).
Measurement of Intracellular Ca
2+ fluorescence intensity [Ca 2+ ]i was measured by using the fluorescent dye Fluo-3/AM (19, 20) . Twenty-four hours before the experiment, VSMCs were incubated in serum-free medium. On the day of the experiment, cells were washed twice with fluorescence buffer (140 mmol/L NaCl, 1 mmol/L MgCl 2 , 1.5 mmol/L CaCl 2 , 5 mmol/L KCl, 10 mmol/L HEPES, 5 mmol/L glucose, pH 7.4). The cells were loaded with 10 μmol/L Fluo-3/AM and 0.02% pluronic F-127 (Sigma, USA) in darkness for 40 minutes at 37°C in fluorescence buffer. Excessive dye was removed by rinsing twice with fluorescence buffer. Experiments were performed at room temperature under laser scanning confocal microscope (FV-500, Olympus, Japan). Each experiment was repeated at least 3 times, and at least 20 cells were tested. Changes of fluorescence intensity (FI) of individual cells were detected in FLUO3 mode of the microscope, scanning one frame every second and scanning 320 frames every cell. And peak FI value of each cell was recorded.
Cellular proliferation assessment VSMC proliferation was determined by a BrdU cell proliferation assay kit (Exalpha Biologicals, Inc, USA). Cells (2.5 × 10 3 /well) were plated into 96-well plates. Prior to experiments, cells were growth-arrested in serum-deprived DMEM for 24 h (time 0). Cells were then stimulated with test reagents or antibodies. Each reagent or antibody was tested in 5 wells. Remain procedures were performed as described in the kit protocol.
Statistical Analysis
Data were expressed as mean ± standard error of the mean (SEM). Student's t test was used for comparison of variables between groups. Significance of incidence was checked by the χ 2 test. Values of p < 0.05 were considered to denote statistical significance.
Results
Incidence of the AT 1 -AAs
Ten patients (10/22) in the RH group and 3 patients (3/24) in the NRH group had detectable AT 1 -AAs (Figure 1) . The difference between the prevalence of two groups was statistically significant (χ 2 = 4.630, ν = 1, p < 0.05). There were 3 normotensives (3/37) also had positive AT 1 -AAs, and all of them were completely healthy. There were no significant difference in the prevalence between the NRH group and normotensives. Sera of 5 autoantibody-positive hypertensive patients (3 from the RH group and 2 from the NRH group) were investigated 6 months later. All of them remained positive, even if BP was well controlled.
Recognition of the AT 1 receptor by AT 1 -AAs
We showed the fluorescent photomicrographs of VSMCs exposed to AT 1 -AAs and antibodies from negative serum (Figure 2 ). FITC-labeled anti-human antibody (secondary antibody) produced the green staining in VSMCs, which were incubated with AT 1 -AAs at 1:40 dilution previously (Figure 2A ). But the same cells exposed to the antibodies from AT 1 -AAs negative serum produced the negative staining ( Figure 2B ). The results indicated AT 1 -AAs could bind the antigen of VSMCs, whereas the IgG from negative serum could not. 6 versus (1.14 ± 0.14) × 10 6 , p < 0.05, Figure 4E ]. Under laser scanning confocal microscopy, the contour of VSMCs loaded with Fluo-3/AM was clear. After addition of AT 1 -AAs at 1:10 dilution, there was an instant and obvious increase of FI in both cytoplasmic and nuclear compartments; FI increased immediately but didn't return to baseline level through observation. Time-lapse confocal Fluo-3/AM Ca 2+ images were shown in Figure 5 .
VSMCs were treated with different dilutions of AT 1 -AAs (1:100, 1:40, 1:20 and 1:10), and AT 1 -AAs from 3 different patients (two patients from the RH group and one patient from the NRH group) all showed a dose-dependent manner in increased Ca 2+ FI ( Figure 6 ). The data suggested that AT 1 -AAs significantly stimulated Ca 2+ mobilization of VSMCs and showed a dose-dependent manner, whereas control IgG did not. 
Increased [Ca
.031, p < 0.05). And proliferation induced by AT 1 -AAs could also be blocked by peptide P2 (1.244 ± 0.038 versus 1.068 ± 0.036, p < 0.05).
Discussion
The important findings in this study were that AT 1 -AAs from hypertensives stimulated Ca 2+ increasing in VSMCs and were related to therapy resistance in hypertension. We showed AT 1 -AAs were present in 10/22 patients with refractory hypertension. In comparison, in the subgroup of nonrefractory hypertension, incidence of the antibodies was 3/24. In a larger hypertensive population we analyzed earlier, 42/98 patients with refractory hypertension got positive AT 1 -AAs, which were much higher than incidence in the NRH group and health control (8) . The positive rate of AT 1 -AAs in refractory hypertension was significantly higher than the rate in well-controlled hypertension. All the clinical data indicated refractory hypertension was highly associated with the autoantibodies against the AT 1 receptor.
Fu et al. first found AT 1 -AAs were present in the circulation of hypertensives and might be involved in the pathogenesis of malignant hypertension (7) . The antibodies displayed a positive chronotropic effect on cultured neonatal rat cardiomyocytes and were proven to have an agonistic character as Ang II. The definitive role of AT 1 -AAs in the pathogenesis of primary hypertension is unclear, but Ang II is known to cause the contraction of VSMCs in blood vessels. And increased [Ca 2+ ]i is the signal activating the contractile apparatus of VSMCs to cause a contraction (13) . We studied the AT 1 receptor agonistic response with the trace of intracellular free Ca 2+ of VSMCs when exposed to AT 1 -AAs. The autoantibody exhibited cross-reactivity with rat AT 1A receptor of VSMCs, and behaved as an agonist. AT 1 -AAs from all 3 different sera were capable of leading the increase intracellular Ca 2+ mobilization and showed a dose-dependent manner. This effect was similar to that of Ang II. As an increase in [Ca 2+ ]i stimulates VSMC contraction, all the experiments in vitro indicated AT 1 -AA was a vasoconstrictor to elevate the peripheral resistance. The specificity of the responses of VSMCs induced by AT 1 -AAs via the AT 1 receptor was confirmed by using losartan as well as a peptide from the second extracellular loop of the AT 1 receptor. In conclusion, AT 1 -AAs increase Ca 2+ in VSMCs via activation of the AT 1 receptor and may play a role in elevating peripheral vascular resistance.
Ang II is believed to play a pivotal role in the development of hypertension since it acts as a growth promoting factor in VSMCs and results in vascular remodeling (21, 22) . According to present data, AT 1 -AAs were suggested to have similar effects. Dechend et al reported that AT 1 -AAs induced signaling in vascular cells including AP-1 and NF-κB activation (10, 11) . Both of these nuclear factors participate in inflammation (23, 24) . Wallukat et al. found monocytes, which were pivotal to vascular wall inflammatory processes, could be stimulated by AT 1 -AAs to adhere, produce tissue mol/L) prior to AT 1 -AAs and serum-free DMEM supplemented with excessive peptide P2 prior to AT 1 -AAs. And the proliferation of VSMCs was determined by Brdu cell proliferation assay kit as decribed in material and methods factor, and probably reactive oxygen species (25) . Both of their findings indicated that AT 1 -AAs involved in the inflammation of vascular walls, which is an important mechanism of vascular remodeling. In the animal model, the antibodies against the AT 1 receptor produced by active immunization with the second extracellular loop of the human AT 1 receptor were able to induce pathological structural changes of artery after one year (26) . All the results in the laboratory suggest AT 1 -AAs may play a role in vascular remodeling. Whether or not AT 1 -AAs contribute to vascular remodeling in hypertension needs a long term follow-up with carotid intima-media thickening of the patients who have positive antibody.
Refractory hypertension is unusual in clinical practice, thanks to the widespread availability of antihypertensive drugs. However, its prevalence increases with increasing severity of BP and high prevalence of target organ damage (27) . A maximum dose of drug or combinations of three or more drugs seems to be effective in this situation. But this therapy is not cost-effective and will bring many side effects of drug; both will lead to poor compliance of patients. So before treatments, there should be proper evaluation of such patients to determine the factor(s) responsible for resistance to therapy (28) .
In present study, many factors including renal diseases, excessive sodium intake, alcohol, sleep apnea and obesity were all excluded before the therapy. AT 1 -AAs seemed to be an independent factor. Based on this recognition, AT 1 receptor blockers (ARBs) are appropriate antihypertensive drugs for the individuals with positive antibodies. Some refractory hypertensives with positive antibodies had already benefited from the use of ARBs in our earlier study (29) . The antibody is also common in malignant hypertension. Fu and coworkers reported that AT 1 -AAs were present in 14% patients with malignant essential hypertension and 33% patients with malignant secondary hypertension (7) . Very elevated BP is usually accompanied by acute and severe renal failure. Under the condition of highly increased serum creatinine and potassium, the use of ARBs is often reluctant. According to our practice, ARBs were beneficial and safe for the patients with the positive antibodies, when the serum creatinine and potassium levels were monitored. Since our practices were neither randomly assigned nor blinded and subjects were too small, we could not draw a firm conclusion that ARBs could benefit patients with positive antibody in refractory or malignant hypertension. As the effect of AT 1 -AAs can be neutralized by a peptide from the second extracellular loop of the AT 1 receptor, immune adsorption (IA) is an alternative. IA had been used to remove autoantibody against the α1-adrenoreceptor, which is another important autoantibody in refractory hypertension and had been proved effective (30) . Because of its high cost, IA can not be used widely.
Even if the presence of AT 1 -AAs is a common event in patients with refractory and malignant hypertension, the occurrence of autoantibody can not only be explained as a consequence of vascular damages of hypertension and the release of immunogenic parts of the receptor. Because we also observed 3 of 37 normotensives had positive response in ELISA and some BP well-controlled patients always maintained positive antibodies in circulation. And there was little evidence to support molecular mimicry theory to explain the AT 1 receptor autoantibody phenomenon, which could well explain the antibodies directed against other G-protein receptors in Chagas' disease or in myasthenia gravis (31, 32) . There were several speculations on the origin of AT 1 -AAs in previous works. In preeclampia, diminished placental perfusion could alter the AT 1 receptor expression in an aberrant fashion, thereby permitting autoantibody production (6) . And in allograft renal-rejection subjects, posttransplantation reperfusion injury may alter the intragraft expression of AT 1 receptor, change its density, or cause conformational changes; a permissive environmental phenomenon might enhance local intragraft immunoreactivity owing to an activated innate immune response (33) . It seems that both of the speculations could not explain the AT 1 -AAs phenomenon in hypertension. We hypothesize that the interactions between underlying multiple genotypes and the environment factors (hypertension, pregnancy, posttransplantation reperfusion and others) may lead to an altered immune response to self antigens including the AT 1 receptors (34) . To prove the hypothesis, we intend to set up a bloodsample library of the individuals with positive antibodies to do further research.
In summary, we found 10/22 patients with refractory hypertension and 3/24 patients with non-refractory hypertension had autoantibodies directed against the AT 1 receptor. We showed that the antibodies could lead an increase intracellular Ca 2+ mobilization and induce proliferation of VSMCs through the AT 1 receptor. The results indicated the autoantibody might play a role in the elevation of peripheral vascular resistance and in the development of vascular remodeling in patients with primary hypertension, especially in the patients with refractory hypertension. The detection of such autoantibody may assist in the selection of an appropriate antihypertensive drug for an individual.
